Nintedanib is a receptor tyrosine kinase inhibitor which suppresses downstream signaling of FGFR and VEGFR, thereby dampening pro-fibrotic processes in IPF patients [35]. The gene discussed is KDR; the disease is idiopathic pulmonary fibrosis.